TABLE 2.
Jadad scale of the included trials.
| Author year | JADAD | ||||
|---|---|---|---|---|---|
| a | b | c | D | T | |
| Heber et al. (1999) | 1 | 1 | 2 | 1 | 5 |
| Zhao et al. (2003) | 1 | 1 | 2 | 0 | 4 |
| Lin et al. (2005) | 1 | 1 | 2 | 1 | 5 |
| Becker et al. (2009) | 2 | 2 | 1 | 1 | 6 |
| Yang et al. (2009) | 1 | 1 | 1 | 1 | 4 |
| Bogsrud et al. (2010) | 1 | 1 | 2 | 1 | 5 |
| Halbert et al. (2010) | 2 | 2 | 2 | 1 | 7 |
| Karl et al. (2012) | 2 | 2 | 1 | 1 | 6 |
| Cicero et al. (2013) | 2 | 2 | 1 | 1 | 6 |
| Verhoeven et al. (2013) | 2 | 1 | 2 | 1 | 6 |
| Moriarty et al. (2014) | 2 | 2 | 2 | 1 | 7 |
| Cui et al. (2015) | 1 | 1 | 1 | 1 | 4 |
| Wang et al. (2015) | 1 | 1 | 1 | 1 | 4 |
| Heinz et al. (2016) | 1 | 1 | 2 | 1 | 5 |
| Cicero et al. (2017) | 2 | 2 | 2 | 1 | 7 |
From a to d, dimension of the Jadad scale. Points awarded: a, study was described as randomized, 1 point; the method was appropriate (table of random numbers, computer generated, etc.), 2 points; b, study used allocation concealment, 1 point; the method was appropriate (taken by the third one who wasn’t researcher or patient, opaque envelope, etc.), 2 points; c, study was described as double blind, 1 point; the method was appropriate (identical placebo, active placebo, dummy, etc.), 2 points; d, study reported withdraws and dropouts and described the reasons. T, total.